Journal article
The efficacy of dihydroartemisinin-piperaquine and artemether-lumefantrine with and without primaquine on Plasmodium vivax recurrence: A systematic review and individual patient data meta-analysis
Robert J Commons, Julie A Simpson, Kamala Thriemer, Tesfay Abreha, Ishag Adam, Nicholas M Anstey, Ashenafi Assefa, Ghulam R Awab, J Kevin Baird, Bridget E Barber, Cindy S Chu, Prabin Dahal, Andre Daher, Timothy ME Davis, Arjen M Dondorp, Matthew J Grigg, Georgina S Humphreys, Jimee Hwang, Harin Karunajeewa, Moses Laman Show all
PLOS Medicine | PUBLIC LIBRARY SCIENCE | Published : 2019
Abstract
BACKGROUND: Artemisinin-based combination therapy (ACT) is recommended for uncomplicated Plasmodium vivax malaria in areas of emerging chloroquine resistance. We undertook a systematic review and individual patient data meta-analysis to compare the efficacies of dihydroartemisinin-piperaquine (DP) and artemether-lumefantrine (AL) with or without primaquine (PQ) on the risk of recurrent P. vivax. METHODS AND FINDINGS: Clinical efficacy studies of uncomplicated P. vivax treated with DP or AL and published between January 1, 2000, and January 31, 2018, were identified by conducting a systematic review registered with the International Prospective Register of Systematic Reviews (PROSPERO): CRD42..
View full abstract
Grants
Awarded by Australian NHMRC Senior Research Fellowship
Awarded by NHMRC
Awarded by OPRA - Bill & Melinda Gates Foundation
Awarded by Australian Centre for Research Excellence on Malaria Elimination (ACREME) - National Health and Medical Research Council of Australia
Funding Acknowledgements
RJC is supported by a Postgraduate Australian National Health and Medical Research Council Scholarship (NHMRC) and a RACP NHMRC Kincaid-Smith Scholarship. RNP is a Wellcome Trust Senior Fellow in Clinical Science (200909). JAS is funded by an Australian NHMRC Senior Research Fellowship 1104975, NMA by an NHMRC Senior Principal Research Fellowship 1135820, and MJG by an NHMRC Early Career Fellowship 1138860. KT is funded by the Asia Pacific Malaria Elimination Network (APMEN) and OPRA clinical trial funding, supported by the Bill & Melinda Gates Foundation (OPP1164105 and OPP1054404). WWARN is funded by Bill and Melinda Gates Foundation and Exxon Mobil Foundation grants. This work was supported by the Australian Centre for Research Excellence on Malaria Elimination (ACREME), funded by the National Health and Medical Research Council of Australia (1134989). The funders had no role in the study design, data collection and analysis, decision to publish, or the preparation of the manuscript.